デフォルト表紙
市場調査レポート
商品コード
1442904

スマートピル - 世界市場の考察、競合情勢、市場予測(2030年)

Smart Pills - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
スマートピル - 世界市場の考察、競合情勢、市場予測(2030年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のスマートピルの市場規模は、2024年~2030年の予測期間にCAGRで11.34%の大幅な成長が見込まれています。さまざまな要因が重なり合ってスマートピルの需要を促進しており、中でも老年人口の増加や、がんや糖尿病といった生活習慣病の罹患率の上昇が大きな影響を及ぼしています。このような人口動態の変化は、先進の医療ソリューションに対する差し迫ったニーズを生み出し、スマートピルの採用を促進しています。

さらに、市場は研究開発活動の高まりやスマートピルの技術革新に充てられる資金の増加から恩恵を受ける見込みです。マイクロカメラの統合、小型化、先進のマイクロプロセッサーの普及などの技術の進歩は、全体的な市場情勢を増大させる上で極めて重要です。こうした技術的強化は、スマートピルの診断および治療の能力を高め、スマートピルを現代医療における重要なツールとしています。

低侵襲処置に対する需要の急増と患者の利便性の重視は、市場の伸びをさらに加速させています。これらの要因の重なりは、市場を前進させるだけでなく、医療診断と治療手法に革命をもたらすスマートピルの変革の可能性をも明示しています。

さらに、スマートピル市場は新製品の発売と承認の流入により、持続的な成長が見込まれます。このダイナミックな情勢は、革新的なソリューションを通じてアンメットメディカルニーズへの対応にますます焦点が当てられていることを特徴としており、それによって市場の拡大が促進されます。2024年~2030年の予測期間は、スマートピル提供の強固なエコシステムが見られ、医療産業におけるこの変革的なセグメントの全体的な成長と発展に大きく寄与すると予測されます。

スマートピルの市場力学

世界中での多様な消化器系疾患の急増が、スマートピル市場を大きく押し上げる見込みです。European Federation of Crohn's and Ulcerative Colitis Associations(EFCCA)の近年のデータでは、世界で1,000万人という驚異的な数の人々が炎症性腸疾患(IBD)と闘病していることが明らかになっています。さらに、National Institute for Health and Care Excellenceは、過敏性腸症候群(IBS)は通常、英国では20歳~30歳で発症し、一般人口における有病率は年間10%~20%であると報告し、状況の重大さを強調しています。警戒すべきことに、IBSの症状があっても受診を見合わせる人が多く、本当の有病率はより高い可能性があると考えられています。

GLOBOCAN(2021)によると、消化器系の恐るべき課題である大腸がんは、2020年に世界で193万1,590人が新たに罹患しました。このような世界中での消化器疾患の急増は、診断と治療の両面で極めて重要な役割を果たすスマートピルに対する需要の増大を示しています。

患者の低侵襲処置への選好の高まりが、スマートピル市場をさらに後押ししています。スマートピルは、先進のカプセル内視鏡検査、正確なドラッグデリバリー、シームレスな遠隔患者モニタリングといった際立った利点を提供します。これらの特性は、消化器疾患やがんの治療パラダイムにおけるスマートピルの採用の拡大に寄与しています。

市場力学は、業界参入企業による研究開発(R&D)への多額の投資と、提携や買収などの戦略的取り組みによってさらに活性化しています。注目すべき例として、2021年1月のEtectRxとPear Therapeuticsの提携があります。この提携は、医薬品に組み込まれたワイヤレスセンサーとデジタル治療薬を統合し、服薬アドヒアランスデータと革新的な治療アプローチを組み合わせることを目的としています。

結論として、消化器疾患の有病率の上昇、患者の低侵襲処置へのシフト、業界の戦略的取り組みの重なりにより、スマートピル市場は2024年~2030年に力強い成長が見込まれます。継続的な技術の進歩や、研究とパートナーシップにおける協調的活動は、消化器医療の進化する情勢に対処するスマートピルの変革可能性を明示しています。

当レポートでは、世界のスマートピル市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 スマートピル市場レポートのイントロダクション

第2章 スマートピル市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 スマートピル市場の主な要因の分析

  • スマートピル市場の促進要因
  • スマートピル市場の抑制要因と課題
  • スマートピル市場の機会

第5章 スマートピル市場のポーターのファイブフォース分析

第6章 スマートピル市場のレイアウト

  • 製品別
    • カプセル
    • ソフトウェア、アクセサリ
  • 用途別
    • カプセル内視鏡
    • 患者モニタリング
    • ドラッグデリバリー
  • 疾患別
    • クローン病
    • 小腸腫瘍
    • 遺伝性ポリポーシス症候群
    • 消化管出血
    • その他
  • エンドユーザー別
    • 病院・診療所
    • 診断センター
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第7章 スマートピル市場の企業と製品のプロファイル

  • Medtronic
  • Capso Vision Inc.
  • Olympus America
  • Hoya (Pentax Medical)
  • etectRx
  • Check-Cap
  • INTROMEDIC
  • HQ, Inc.
  • Koninklijke Philips N.V.
  • Novartis AG
  • BodyCAP
  • Medisafe
  • Otsuka America Pharmaceutical, Inc.
  • JINSHAN Science & Technology
  • Proteus Digital Health, Inc.
  • AnX Robotics.
  • Medimetrics S.A. de C.V.
  • BioCam
  • BDD Limited
  • RF Co., Ltd.

第8章 KOLの見解

第9章 プロジェクトアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Smart Pills Market in Global (2021-2030)
  • Table 3: Smart Pills Market in Global by Product (2021-2030)
  • Table 4: Smart Pills Market in Global by Application (2021-2030)
  • Table 5: Smart Pills Market in Global by Disease (2021-2030)
  • Table 6: Smart Pills Market in Global by End-User (2021-2030)
  • Table 7: Smart Pills Market in Global by Geography (2021-2030)
  • Table 8: Smart Pills Market in North America (2021-2030)
  • Table 9: Smart Pills Market in the US (2021-2030)
  • Table 10: Smart Pills Market in Canada (2021-2030)
  • Table 11: Smart Pills Market in Mexico (2021-2030)
  • Table 12: Smart Pills Market in Europe (2021-2030)
  • Table 13: Smart Pills Market in France (2021-2030)
  • Table 14: Smart Pills Market in Germany (2021-2030)
  • Table 15: Smart Pills Market in the United Kingdom (2021-2030)
  • Table 16: Smart Pills Market in Italy (2021-2030)
  • Table 17: Smart Pills Market in Spain (2021-2030)
  • Table 18: Smart Pills Market in the Rest of Europe (2021-2030)
  • Table 19: Smart Pills Market in Asia-Pacific (2021-2030)
  • Table 20: Smart Pills Market in China (2021-2030)
  • Table 21: Smart Pills Market in Japan (2021-2030)
  • Table 22: Smart Pills Market in India (2021-2030)
  • Table 23: Smart Pills Market in Australia (2021-2030)
  • Table 24: Smart Pills Market in South Korea (2021-2030)
  • Table 25: Smart Pills Market in the Rest of Asia-Pacific (2021-2030)
  • Table 26: Smart Pills Market in the Rest of the World (2021-2030)
  • Table 27: Smart Pills Market in the Middle East (2021-2030)
  • Table 28: Smart Pills Market in Africa (2021-2030)
  • Table 29: Smart Pills Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Smart Pills Market in Global (2021-2030)
  • Figure 3: Smart Pills Market in Global by Product (2021-2030)
  • Figure 4: Smart Pills Market in Global by Application (2021-2030)
  • Figure 5: Smart Pills Market in Global by Disease (2021-2030)
  • Figure 6: Smart Pills Market in Global by End-User (2021-2030)
  • Figure 7: Smart Pills Market in Global by Geography (2021-2030)
  • Figure 8: Smart Pills Market in North America (2021-2030)
  • Figure 9: Smart Pills Market in the US (2021-2030)
  • Figure 10: Smart Pills Market in Canada (2021-2030)
  • Figure 11: Smart Pills Market in Mexico (2021-2030)
  • Figure 12: Smart Pills Market in Europe (2021-2030)
  • Figure 13: Smart Pills Market in France (2021-2030)
  • Figure 14: Smart Pills Market in Germany (2021-2030)
  • Figure 15: Smart Pills Market in the United Kingdom (2021-2030)
  • Figure 16: Smart Pills Market in Italy (2021-2030)
  • Figure 17: Smart Pills Market in Spain (2021-2030)
  • Figure 18: Smart Pills Market in the Rest of Europe (2021-2030)
  • Figure 19: Smart Pills Market in Asia-Pacific (2021-2030)
  • Figure 20: Smart Pills Market in China (2021-2030)
  • Figure 21: Smart Pills Market in Japan (2021-2030)
  • Figure 22: Smart Pills Market in India (2021-2030)
  • Figure 23: Smart Pills Market in Australia (2021-2030)
  • Figure 24: Smart Pills Market in South Korea (2021-2030)
  • Figure 25: Smart Pills Market in the Rest of Asia-Pacific (2021-2030)
  • Figure 26: Smart Pills Market in the Rest of the World (2021-2030)
  • Figure 27: Smart Pills Market in the Middle East (2021-2030)
  • Figure 28: Smart Pills Market in Africa (2021-2030)
  • Figure 29: Smart Pills Market in South America (2021-2030)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0690

Smart Pills Market By Product (Capsules And Software And Accessories), Application (Capsule Endoscopy [Small Bowel Video Capsule Endoscopy And Colon Capsule Endoscopy], Patient Monitoring, And Drug Delivery), Disease (Crohn's Disease, Small Bowel Tumors, Inherited Polyposis Syndromes, GI Bleeding, And Others), End-Users (Hospitals & Clinics, Diagnostic Centers, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of gastrointestinal diseases and the increasing demand of minimally invasive approaches across the globe

The global smart pills market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 11.34% during the forecast period from 2024 to 2030. A confluence of factors propels the demand for smart pills, with a notable impact stemming from the rising geriatric population and the escalating incidence of lifestyle-related diseases such as cancer and diabetes. This demographic shift is creating a pressing need for advanced healthcare solutions, thereby fostering the adoption of smart pills.

Moreover, the market is set to benefit from heightened research and development endeavors, coupled with increased funding dedicated to smart pill innovation. Technological strides, including the integration of micro-cameras, miniaturization, and the widespread availability of advanced microprocessors, are pivotal in augmenting the overall market landscape. These technological enhancements enhance the diagnostic and therapeutic capabilities of smart pills, positioning them as vital tools in modern healthcare.

The surge in demand for minimally invasive procedures and a growing emphasis on patient convenience further amplify the market's trajectory. The convergence of these factors not only propels the market forward but also underscores the transformative potential of smart pills in revolutionizing medical diagnostics and treatment methodologies.

Furthermore, the smart pills market is poised for sustained growth due to an influx of new product launches and approvals. The dynamic landscape is characterized by an increasing focus on addressing unmet medical needs through innovative solutions, thereby driving the market's expansion. The forecast period from 2024 to 2030 is expected to witness a robust ecosystem of smart pill offerings, contributing significantly to the overall growth and development of this transformative segment within the healthcare industry.

Smart Pills Market Dynamics:

The burgeoning prevalence of diverse gastrointestinal diseases globally is poised to significantly boost the smart pills market. A compelling illustration is provided by recent data from the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA), revealing that a staggering 10 million individuals worldwide grapple with Inflammatory Bowel Disease (IBD). Furthermore, the National Institute for Health and Care Excellence underscores the gravity of the situation, reporting that Irritable Bowel Syndrome (IBS) typically emerges between ages 20 and 30 in the United Kingdom, with a prevalence of 10% to 20% in the general population annually. Alarmingly, it is believed that many with IBS symptoms forego medical consultation, indicating a potentially higher true prevalence.

Colorectal cancer, a formidable gastrointestinal challenge, saw 1,931,590 new global cases in 2020 according to GLOBOCAN 2021. This collective surge in gastrointestinal ailments globally underscores the escalating demand for smart pills, which play a pivotal role in both diagnosis and treatment.

The growing preference for minimally invasive procedures among patients propels the smart pills market further. Smart pills offer distinctive advantages such as advanced capsule endoscopy, precise drug delivery, and seamless remote patient monitoring. These attributes contribute to the increasing adoption of smart pills in the treatment paradigm for gastrointestinal diseases and cancer.

Market dynamics are further catalyzed by substantial investments in Research and Development (R&D) by industry players, coupled with strategic initiatives like partnerships and acquisitions. A noteworthy example is the collaboration between EtectRx and Pear Therapeutics in January 2021. This partnership aims to integrate wireless sensors embedded in medications with digital therapeutics, combining medication adherence data with innovative therapeutic approaches.

In conclusion, the confluence of rising gastrointestinal disease prevalence, the patient shift towards minimally invasive procedures, and strategic industry initiatives position the smart pills market for robust growth from 2024 to 2030. The continual advancements in technology and concerted efforts in research and partnerships underscore the transformative potential of smart pills in addressing the evolving landscape of gastrointestinal healthcare.

However, risks related to the smart pills, the high costs associated with the device, and others may restrict the growth of the overall smart pills market.

Smart Pills Market Segment Analysis:

Smart pills Market by Product (Capsules and Software and Accessories), Application (Capsule Endoscopy [Small Bowel Video Capsule Endoscopy and Colon Capsule Endoscopy], Patient Monitoring, and Drug Delivery), Disease (Crohn's Disease, Small Bowel Tumors, Inherited Polyposis Syndromes, GI Bleeding, and Others), End-Users (Hospitals & Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Within the application segment of the smart pills market, the small bowel video capsule endoscopy category is poised to capture a substantial revenue share in 2023, driven by its inherent advantages and diverse applications. Small bowel video capsule endoscopy is a non-invasive procedure employing a miniature wireless camera to capture images of the digestive tract, particularly the small intestine. This innovative approach involves the patient swallowing a capsule, akin to a large pill, housing a camera.

The miniature camera within the small bowel video capsule endoscopy system, encapsulated in a vitamin-sized pill, travels through the digestive tract, capturing thousands of images transmitted to a recorder worn on a belt around the patient's waist. Not only does this procedure offer a detailed view of the small intestine, but it also eliminates the need for invasive measures, aligning with the growing trend towards minimally invasive healthcare technologies.

Furthermore, ongoing advancements in small bowel video capsule endoscopes, particularly in batteries and onboard memory, contribute to their suitability for prolonged usage, enhancing diagnostic capabilities. The market benefits from the presence of technologically advanced devices designed for optimal visualization of the small intestine. For instance, CapsoCam Plus, a product by CapsoVision, stands out by providing a full 360º panoramic direct lateral view of the small bowel mucosa, thereby improving diagnostic accuracy.

The momentum in this segment is further fueled by a series of product launches, regulatory approvals, and strategic initiatives. A notable instance is Medtronic plc's PillCam Small Bowel 3 system, which received clearance from the United States Food and Drug Administration (FDA) in November 2021 for remote endoscopy procedures. The ingestible camera in this capsule facilitates comprehensive visualization of the small bowel, exemplifying the continuous innovation within the field.

In light of these factors, the small bowel video capsule endoscopy category is anticipated to experience substantial growth, contributing significantly to the overall expansion of the smart pills market throughout the forecast period. The convergence of technological advancements, non-invasiveness, and strategic industry moves positions this category as a key driver in shaping the future landscape of smart medical solutions.

North America is expected to dominate the overall Smart Pills Market:

In the year 2023, North America is anticipated to secure the leading share in the smart pills market, driven by several pivotal factors that underscore the region's prominence. The prevalence of chronic diseases, particularly gastrointestinal ailments and associated cancers, stands out as a key growth driver. This is substantiated by the International Foundation for Gastrointestinal Disorders (IFFGD) 2021 report, revealing that 25 to 45 million individuals in the United States were affected by irritable bowel syndrome during that year.

The region's receptiveness to technologically advanced solutions, aiming to streamline patient care, plays a crucial role. The widespread adoption of such solutions is facilitated by a large and discerning customer base, further complemented by the rapidly growing geriatric population. Regulatory approvals for innovative devices, coupled with heightened awareness regarding disease diagnosis through smart pill technology, further contribute to the region's prosperous outlook.

The International Foundation for Gastrointestinal Disorders (IFFGD) report highlights the escalating burden of Inflammatory Bowel Disease (IBD) in Canada, projecting an increase from 322,600 people affected in 2023 to 470,000 in 2035. This trend underscores the growing demand for smart pills for both diagnosis and treatment in response to the rising prevalence of gastrointestinal diseases.

Notably, the region benefits from the presence of key industry players, fostering a conducive environment for product development activities. Additionally, the United States Food and Drug Administration (FDA) has been instrumental in shaping the market trajectory by granting approvals for innovative technologies. An illustrative example is the FDA's clearance in December 2019 for etectRx's ID-CAP System - a pill embedded with sensors that wirelessly communicates with an external system, revolutionizing remote health monitoring without physical contact.

In light of these factors, the smart pills market in North America is poised for substantial growth during the forecast period from 2024 to 2030. The confluence of increasing disease prevalence, regulatory support, technological advancements, and a robust healthcare ecosystem positions the region as a pivotal player in driving the evolution of smart medical solutions.

Smart Pills Market Key Players:

Some of the key market players operating in the smart pills market include Medtronic, Capso Vision Inc., Olympus America, Hoya (Pentax Medical), etectRx, Check-Cap, INTROMEDIC, HQ, Inc., Koninklijke Philips N.V., Novartis AG, BodyCAP, Medisafe, Otsuka America Pharmaceutical, Inc., JINSHAN Science & Technology, Proteus Digital Health, Inc., AnX Robotics, Medimetrics S.A. de C.V., BioCam, BDD Limited, RF Co., Ltd., and others.

Recent Developmental Activities in the Smart Pills Market:

  • In February 2023, AnX Robotica Corp. (US) launched the NaviCam Small Bowel System in the US. The NaviCam SB System utilizes aspherical lens technology to reduce distortion and enhance the field of vision, a critical component in the diagnosis of small bowel disease.
  • In 2021, Check-Cap (Israel) expanded C-Scan's manufacturing capacity and on-premises production line, while also remedying technical issues from a single source supplier. The company significantly expanded its production line to support its US pivotal study.
  • In June 2020, AnX Robotica Corp. was granted by the FDA De-Novo classification for its NaviCam Magnetically Controlled Capsule Endoscopy (MCCE) System. It is the first-of-its-kind system that allows complete, real-time visualization of the stomach utilizing a pill-sized capsule containing a camera and is remote-controlled by the physician using proprietary magnetic technologies.
  • In December 2020, CapsoVision Inc., achieved the International Standard Organization (ISO) 27001 security certification. The scope of the certification includes CapsoVision's headquarters and the company's CapsoCloud software. This certification validates the company's long-term commitment to the protection of customer data.

Key Takeaways from the Smart Pills Market Report Study

  • Market size analysis for current smart pills market size (2023), and market forecast for 6 years (2024-2030)
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global smart pills market.
  • Various opportunities available for the other competitors in the smart pills market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current smart pills market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for smart pills market growth in the coming future?

Target Audience who can be benefited from this Smart Pills Market Report Study

  • Smart pill product providers
  • Research organizations and consulting companies
  • Smart pills-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in smart pills
  • Various End-users who want to know more about the smart pills market and the latest technological developments in the smart pills market.

Frequently Asked Questions for the Smart Pills Market:

1. What are smart pills?

Smart pills, also known as digital pills or ingestible sensors, are medical capsules or tablets that contain embedded sensors, cameras, or other monitoring devices. These technological components allow the smart pills to collect and transmit data about physiological conditions, medication adherence, and other relevant information from inside the human body. The primary purpose of smart pills is to enhance medical diagnostics, patient monitoring, and drug delivery. They are designed to provide healthcare professionals with real-time information about a patient's health status and response to medication.

2. What is the market for global smart pills?

The global smart pills market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 11.34% during the forecast period from 2024 to 2030.

3. What are the drivers for the global smart pills market?

The demand for smart pills is primarily being boosted by the increasing prevalence of increasing prevalence of chronic diseases, high demand for minimally invasive procedures, an increase in focus on patient convenience, technological development including miniaturization of integrated circuits, increasing product launches and approvals, and others thereby contributing to the overall growth of the smart pills market during the forecast period from 2024-2030.

4. Who are the key players operating in the global smart pills market?

Some of the key market players operating in the smart pills market include Medtronic, Capso Vision Inc., Olympus America, Hoya (Pentax Medical), etectRx, Check-Cap, INTROMEDIC, HQ, Inc., Koninklijke Philips N.V., Novartis AG, BodyCAP, Medisafe, Otsuka America Pharmaceutical, Inc., JINSHAN Science & Technology, Proteus Digital Health, Inc., AnX Robotics, Medimetrics S.A. de C.V., BioCam, BDD Limited, RF Co., Ltd., and others.

5. Which region has the highest share in the smart pills market?

North America is expected to dominate the overall smart pills market during the forecast period from 2024-2030. Owing to factors such as the rising prevalence of chronic diseases and gastrointestinal diseases and related cancers, wide acceptance of technologically advanced solutions to make patient care hassle-free, a large pool of customers, a rapidly growing geriatric population, regulatory approval for new devices, and high awareness about the diagnosis of the disease using smart pill technology among others, the North America smart pills market is expected to growth in coming years.

Table of Contents

1. Smart Pills Market Report Introduction

2. Smart Pills Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Smart Pills Market Key Factors Analysis

  • 4.1. Smart Pills Market Drivers
    • 4.1.1. Increasing prevalence of gastrointestinal disorders
    • 4.1.2. Surging Preference for minimally-invasive device
    • 4.1.3. Technological advancements about smart pills
  • 4.2. Smart Pills Market Restraints and Challenges
    • 4.2.1. Risks related to the smart pills
    • 4.2.2. High cost associated with the device
  • 4.3. Smart Pills Market Opportunities
    • 4.3.1. Growing demand for advanced drug delivery system
    • 4.3.2. Increasing R&D investments and intensive product pipelines

5. Smart Pills Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Smart Pills Market Layout

  • 6.1. By Product
    • 6.1.1. Capsules
    • 6.1.2. Software and Accessories
  • 6.2. By Application
    • 6.2.1. Capsule Endoscopy
      • 6.2.1.1. Small Bowel Video Capsule Endoscopy
      • 6.2.1.2. Colon Capsule Endoscopy
    • 6.2.2. Patient Monitoring
    • 6.2.3. Drug Delivery
  • 6.3. By Disease
    • 6.3.1. Crohn's Disease
    • 6.3.2. Small Bowel Tumors
    • 6.3.3. Inherited Polyposis Syndromes
    • 6.3.4. GI bleeding
    • 6.3.5. Others
  • 6.4. By End-Users
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Diagnostic Centers
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States Smart Pills Market Size in USD million (2021-2030)
      • 6.5.1.2. Canada Smart Pills Market Size in USD million (2021-2030)
      • 6.5.1.3. Mexico Smart Pills Market Size in USD million (2021-2030)
    • 6.5.2. Europe
      • 6.5.2.1. France Smart Pills Market Size in USD million (2021-2030)
      • 6.5.2.2. Germany Smart Pills Market Size in USD million (2021-2030)
      • 6.5.2.3. United Kingdom Smart Pills Market Size in USD million (2021-2030)
      • 6.5.2.4. Italy Smart Pills Market Size in USD million (2021-2030)
      • 6.5.2.5. Spain Smart Pills Market Size in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe Smart Pills Market Size in USD million (2021-2030)
    • 6.5.3. Asia-Pacific
      • 6.5.3.1. China Smart Pills Market Size in USD million (2021-2030)
      • 6.5.3.2. Japan Smart Pills Market Size in USD million (2021-2030)
      • 6.5.3.3. India Smart Pills Market Size in USD million (2021-2030)
      • 6.5.3.4. Australia Smart Pills Market Size in USD million (2021-2030)
      • 6.5.3.5. South Korea Smart Pills Market Size in USD million (2021-2030)
      • 6.5.3.6. Rest of Asia-Pacific Smart Pills Market Size in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW)
      • 6.5.4.1. Middle East Smart Pills Market Size in USD million (2021-2030)
      • 6.5.4.2. Africa Smart Pills Market Size in USD million (2021-2030)
      • 6.5.4.3. South America Smart Pills Market Size in USD million (2021-2030)

7. Smart Pills Market Company and Product Profiles

  • 7.1. Medtronic
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Capso Vision Inc.
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Olympus America
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Hoya (Pentax Medical)
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. etectRx
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Check-Cap
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. INTROMEDIC
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. HQ, Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Koninklijke Philips N.V.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Novartis AG
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. BodyCAP
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Medisafe
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Otsuka America Pharmaceutical, Inc.
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. JINSHAN Science & Technology
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Proteus Digital Health, Inc.
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy
  • 7.16. AnX Robotics.
    • 7.16.1. Company Overview
    • 7.16.2. Company Snapshot
    • 7.16.3. Financial Overview
    • 7.16.4. Product Listing
    • 7.16.5. Entropy
  • 7.17. Medimetrics S.A. de C.V.
    • 7.17.1. Company Overview
    • 7.17.2. Company Snapshot
    • 7.17.3. Financial Overview
    • 7.17.4. Product Listing
    • 7.17.5. Entropy
  • 7.18. BioCam
    • 7.18.1. Company Overview
    • 7.18.2. Company Snapshot
    • 7.18.3. Financial Overview
    • 7.18.4. Product Listing
    • 7.18.5. Entropy
  • 7.19. BDD Limited
    • 7.19.1. Company Overview
    • 7.19.2. Company Snapshot
    • 7.19.3. Financial Overview
    • 7.19.4. Product Listing
    • 7.19.5. Entropy
  • 7.20. RF Co., Ltd.
    • 7.20.1. Company Overview
    • 7.20.2. Company Snapshot
    • 7.20.3. Financial Overview
    • 7.20.4. Product Listing
    • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us